Current Assets
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value
Edwards Lifesciences AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value decreased by 23.8% to $53.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 63.7%, from $146.40M to $53.20M.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2017
Last reportedQ1 2026May 6, 2026
Metric ID:
afs_trading_securities_unrealized_loss_12m_plus_fvHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $58.80M | $81.60M | $393.20M | $1.11B | $1.19B | $1.08B | $953.40M | $843.70M | $622.10M | $432.70M | $295.00M | $214.20M | $146.40M | $116.90M | $90.40M | $69.80M | $53.20M |
| QoQ Change | — | — | — | — | +38.8% | +381.9% | +182.7% | +7.2% | -9.2% | -11.9% | -11.5% | -26.3% | -30.4% | -31.8% | -27.4% | -31.7% | -20.2% | -22.7% | -22.8% | -23.8% |
| YoY Change | — | — | — | — | — | — | — | >999% | >999% | +142.5% | -24.1% | -47.8% | -60.0% | -69.1% | -74.6% | -76.5% | -73.0% | -69.4% | -67.4% | -63.7% |
Range$0.00 – $1.19B
Avg YoY Growth+205.3%
Median YoY Growth-63.7%
Current Streak12 quarters decline
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's afs and trading securities - unrealized loss position (>=12 months) fair value?
- Edwards Lifesciences (EW) reported afs and trading securities - unrealized loss position (>=12 months) fair value of $53.20M in Q1 2026.
- How has Edwards Lifesciences's afs and trading securities - unrealized loss position (>=12 months) fair value changed year-over-year?
- Edwards Lifesciences's afs and trading securities - unrealized loss position (>=12 months) fair value decreased by 63.7% year-over-year, from $146.40M to $53.20M.